SAMHSA Guidance on Medications for Opioid Use Disorder

PUBLISHED: Feb 21, 2018
Relevant to: Ambulatory Care, Behavioral Health, Community Mental Health Centers, Critical Access Hospitals, Hospitals, Medical Office, Pharmacy, Rural Health Clinics

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued new guidance for healthcare and addiction professionals addressing medications for opioid use disorder. The guidance is a part of the Treatment Improvement Protocol (TIP) series that provides science-based best-practice guidance to the behavioral health field. TIPs reflect careful consideration of all relevant clinical and health service research, demonstrated experience, and implementation requirements.

This Treatment Improvement Protocol reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD): methadone, naltrexone, and buprenorphine as well as other strategies and services needed to support recovery for people with OUD.

The guidance includes:

  • Introduction to Medications for Opioid Use Disorder Treatment
  • Addressing Opioid Use Disorder in General Medical Settings
  • Pharmacotherapy for Opioid Use Disorder
  • Partnering Addiction Treatment Counselors with Clients and Healthcare Professionals
  • Resources Related to Medications for Opioid Use Disorder

A link to the new guidance is provided below.

Want to read the full alert and receive alert emails?

Browse Additional Alerts